MG
Therapeutic Areas
AgeneBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AGB101 | Amnestic Mild Cognitive Impairment (MCI) due to Alzheimer's Disease | Phase 2b/3 |
| GABA A α5 PAM Discovery | Spectrum of neurological/psychiatric conditions (e.g., MCI due to AD, schizophrenia) | Discovery |